Vueway, Varibar & Value

Includes a Live Web Event on 01/07/2025 at 1:00 PM (EST)

This Webinar is generously sponsored by Bracco.

image


Date: January 7th, 2025

Time: 1:00 P.M. EST

Speaker: Dr. Steven Sireci

Session Description: The presentation will cover the features and uses of two different Bracco products that each provide unique value to their areas of imaging.  Vueway® (gadopiclenol) is the first true high-relaxivity macrocyclic GBCA approved for use in the U.S., at a low Gd dose of 0.05 mmol/kg.  Varibar® (barium sulfate 40% w/v) is a suite of 5 related barium preparations specifically designed and approved for use in the modified barium swallow (MBS) examination – the only such barium products available. Varibar was used in the clinical validation of the standardized Modified Barium Swallow Impairment Profile (MBSImP™©) protocol for evaluating swallowing disorders in adults.

AHRA Member: free to members 

Non-Member: $25.00

Click here to learn more about the benefits of AHRA Membership.

Key:

Complete
Failed
Available
Locked
Vueway, Varibar & Value
01/07/2025 at 1:00 PM (EST)  |  60 minutes
01/07/2025 at 1:00 PM (EST)  |  60 minutes The presentation will cover the features and uses of two different Bracco products that each provide unique value to their areas of imaging. Vueway® (gadopiclenol) is the first true high-relaxivity macrocyclic GBCA approved for use in the U.S., at a low Gd dose of 0.05 mmol/kg. Varibar® (barium sulfate 40% w/v) is a suite of 5 related barium preparations specifically designed and approved for use in the modified barium swallow (MBS) examination – the only such barium products available. Varibar was used in the clinical validation of the standardized Modified Barium Swallow Impairment Profile (MBSImP™©) protocol for evaluating swallowing disorders in adults.
You must register to access.